AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIE

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER...

Related Keywords

Puerto Rico , Japan , United States , Canada , Michael Strapazon , Jessica Akopyan , Amgen Medinfo , Kyowa Kirin Co Ltd , Amgen , Beigene Ltd , Exchange Commission , Therapeutics Inc , European Union , Teneobio Inc , Studies Showed Sustained Reduction , Combined Studies Evaluated Safety , More Than , Over Five Years After Completing , Longest Studied , Risk Open Label Extension , Eastern Europe , Cardiovascular Open Label Extension , Dow Jones Industrial Average , Best Workplaces , Great Place , Primary Hyperlipidemia , Cardiovascular Outcomes Trial , Pediatric Patients , Prescribing Information , Five Prime Therapeutics , Thousand Oaks ,